When compared with nab-paclitaxel (Abraxane), fluorouracil (5-FU)/leucovorin or gemcitabine led to objective responses in 35% of patients. The (5-FU)/leucovorin group exceeded the prespecified goal of a 4-month progression-free survival (PFS) rate of 50%.1 Additionally, patients randomized to the 5-FU/leucovorin regimen had a 12-month survival rate of 48% versus 41% for gemcitabine-containing therapy. The 18-month survival of the 5-FU/leucovorin group was more than twice that of the gemcitabine arm. Read more . . .